A Fast Path from Innovation to Safe and Effective Medicines

Area of Science:

• Regulatory Science
• Medicines Development
• Pharmacological Innovation

Background:

• Despite progress, unmet medical needs persist, especially in rare diseases, pediatrics, and underserved populations.
• Pharmacological, technological, and regulatory innovations offer hope for new treatments.
• Ensuring scientific progress translates into available, effective medicines is crucial.

Purpose of the Study:

• To present a vision for accelerating the development of safe and effective medicines.
• To highlight the importance of collaboration among regulators, academia, industry, patients, and healthcare professionals.
• To outline strategies for future-proofing the regulatory ecosystem.

Main Methods:

• The European Medicines Agency (EMA) collaborates with stakeholders.
• Strategic initiatives and concrete examples illustrate the process.
• Focus on continuous evolution of regulatory science and patient-centered evidence generation.

Main Results:

• The EMA supports regulatory science evolution.
• Patient-focused refinements in evidence generation and medicines assessments are facilitated.
• Forward-looking initiatives monitor and examine innovative developments.

Conclusions:

• Continued transparent collaboration is key to accelerating medicine availability.
• Future-proofing the regulatory ecosystem ensures scientific progress leads to better health outcomes.
• The vision aims to translate innovation into meaningful health benefits for patients.